|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 417/14 | (2006.01) |
| C07D 417/14 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61K 31/517 | (2006.01) |
| (11) | Number of the document | 3867251 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19791429.4 |
| Date of filing the European patent application | 2019-10-08 | |
| (97) | Date of publication of the European application | 2021-08-25 |
| (45) | Date of publication and mention of the grant of the patent | 2022-09-07 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2019/055091 |
| Date | 2019-10-08 |
| (87) | Number | WO 2020/081282 |
| Date | 2020-04-23 |
| (30) | Number | Date | Country code |
| 201862745502 P | 2018-10-15 | US |
| (72) |
BARDA, David Anthony , US
COATES, David Andrew , US
LINDER, Ryan James , US
PENG, Sheng-Bin , US
ZIA-EBRAHIMI, Mohammad Sadegh , US
|
| (73) |
Eli Lilly and Company ,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
| (54) | KRAS G12C INHIBITORS |
| KRAS G12C INHIBITORS |